EVMN earnings analysis
What we found in EVMN's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Evommune reported zero revenue for Q1 2026, significantly missing expectations as incurred operating losses intensified, marking a 202% increase compared to the prior year. Despite the lack of revenue, the company holds a strong cash position of $307 million, expected to sustain operations through 2028, while continuing its crucial clinical trials with data expected in mid-2026.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Zero Revenue This Quarter
- Evommune reported no revenue for Q1 2026, a decline of $3.0 million (100%) compared to $3.0 million in Q1 2025.
- Increased Operating Losses
- Net loss increased to $21.7 million for Q1 2026, up $7.1 million (49%) from $14.6 million in Q1 2025.
- Maintained Strong Cash Position
- Cash, cash equivalents, and investments totaled $307 million at quarter-end, sufficient to fund operations through 2028.
- Increased R&D Expenses
- Research and development expenses rose to $17.3 million in Q1 2026, an increase of $2.957 million (21%) from $14.4 million in Q1 2025.
- Interest Income Boost
- Other income for Q1 2026 was $2.3 million, showing improvement from $0.5 million in Q1 2025, driven by higher interest income.
- Financing Boost from Private Placement
- EVMN raised $117.2 million from the issuance of common stock in February 2026.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Absence of Product Revenue
- The company has not generated any product-related revenue as of March 31, 2026, continuing its reliance on funding.
- Increasing Operating Expenses
- Total operating expenses rose to $23.9 million for Q1 2026, up $5.9 million (33%) compared to Q1 2025.
- Dependence on Future Financing
- Evommune anticipates needing significant additional funding in the future to continue clinical trials, as they have accumulated a deficit of $242.8 million.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-21.67
What they said about what is next.
No forward guidance was provided.
The filing reads worse than the one before it.
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing EVMN makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever